Defining bioidentical hormones for menopause-related symptoms

Whelan, Anne Marie; Jurgens, Tannis; Trinacty, Melanie

doi:10.4321/s1886-36552011000100003

Cited by 14 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of extensive usage, it appears indicated to define bioidentical hormones, which are also frequently administered, as molecular compounds essentially identical in structure to human hormones [22]. Appropriate usage of HRT involves assessment of balance between benefits and risks [23].…”

Section: Issues Of Hormone Replacement Therapy In Womenmentioning

confidence: 99%

Women, the menopause, hormone replacement therapy and coronary heart disease

Whayne

Mukherjee

2015

Current Opinion in Cardiology

View full text Add to dashboard Cite

show abstract

Section: Issues Of Hormone Replacement Therapy In Womenmentioning

confidence: 99%

Women, the menopause, hormone replacement therapy and coronary heart disease

Whayne

Mukherjee

2015

Current Opinion in Cardiology

View full text Add to dashboard Cite

show abstract

“…Bioidentical hormones are defined as chemical substances that are identical in molecular structure to human hormones [ 14 ]. ‘Bioidentical hormone therapy’ (BHT) is a term generally used to describe plant-derived, hormone formulations (most commonly combinations of progesterone and 17β oestradiol, oestrone or oestriol) specifically compounded for an individual.…”

Section: Introductionmentioning

confidence: 99%

Use of Menopausal Hormone Therapy and Bioidentical Hormone Therapy in Australian Women 50 to 69 Years of Age: Results from a National, Cross-Sectional Study

et al. 2016

View full text Add to dashboard Cite

Menopausal Hormone Therapy (MHT) use in Australia fell by 55% from 2001 to 2005, following the release of large-scale findings on its risks and benefits. Comprehensive national data, including information on overall prevalence of MHT use as well as information on duration of use in Australia have not been reported since the 2004–5 National Health Survey, when 11% of women aged 45+ years were estimated to be current MHT users. No national data are available on prevalence of use of “bioidentical” hormone therapy (BHT). The objective of this study was to determine recent prevalence of MHT and BHT use. A cross-sectional, national, age-stratified, population survey was conducted in 2013. Eligible women, aged 50–69 years, resident in Australia were randomly sampled in 5-year age groups from the Medicare enrolment database (Australia’s universal health scheme). The response rate was 22% based on return of completed questionnaires, and analyses were restricted to 4,389 women within the specified age range. The estimated population-weighted prevalence of current use of MHT was 13% (95%CI 12–14), which was broadly similar to the previously reported national figures in 2004–5, suggesting that the use of MHT in Australia has largely stabilised over the past decade. A total of 39% and 20% of current-users with an intact uterus reported use of oestrogen-progestagen MHT and oestrogen-only MHT, respectively, whereas 77% of hysterectomised current-users used oestrogen-only MHT. Almost three-quarters of current-users [population-weighted prevalence 9% (95%CI 8–10)] had used MHT for ≥5 years. In regard to BHT, estimated population-weighted prevalence of ever use was 6% (95%CI 6–7) and 2% (95%CI 2–3) for current use. The population-weighted prevalence of MHT and BHT combined, in current users in their fifties and sixties was 15% (95%CI 14–16). These data provide a recent national “snapshot” of Australian women’s use of both conventional MHT and of BHT.

show abstract

“…Естрадіол пригнічує сигнальний шлях рецептора ангіотензину II першого типу, знижуючи активність АПФ, справляючи позитивний вплив на експресію білка АПФ-2. Це призводить до захисного впливу на серце, легені, нирки, центральну нервову систему і кишечник [54,55]. Крім того, естрадіол регулює рівень ліпідних медіаторів і пептидів, що беруть участь у процесах, необхідних для адекватної імунної відповіді, підвищуючи ймовірність успішного результату в боротьбі з інфекційним агентом, таким як SARS-CoV-2 [47,49].…”

Section: вплив естрогенів на імунні процесиunclassified

On the use of sex steroids in women during the COVID-19 pandemic

Татарчук¹,

Дубоссарська

Pyrohova

et al. 2021

View full text Add to dashboard Cite

The document was approved at an expanded meeting of the Ukrainian Society of Gynecological Endocrinology with the involvement of all board members and representatives of the Association of Obstetricians-Gynecologists of Ukraine, the Association of Pharmacologists of Ukraine, the Association of Anesthesiologists of Ukraine, as well during the Third Ukrainian School of Gynecological and Reproductive Endocrinology with international participation ISGE 19–20.03.21.The COVID-19 pandemic has significantly impacted medical practice, in terms of organizational and clinical practices, posing a number of complex and contradictory challenges for professionals.This document is the result of the systematization of scientific data available by March 2021 and recommendations of international medical and specialized professional societies on controversial clinical issues in gynecological practice caused by the COVID-19 pandemic, as well as certain issues of safety and ratio of using hormonal drugs. The involvement of experts from professional associations of the obstetric and gynecological field, pharmacology, anesthesiology and vascular surgery and phlebology in the working group made it possible to formulate clinically justified provisions of the position.The position includes three thematic sections: “On the use of estrogen-containing combined hormonal contraceptives (CHC) during the COVID-19 pandemic”; “On the use of menopausal hormone therapy (MHT) during the COVID-19 pandemic”; “On the issue of unregistered compounded bioidentical hormones”. At the beginning of each thematic section, the main conclusions of the consensus position of professional medical associations are presented. According to the data available by March 2021, there is no reason to limit the use of CHC or MHT in healthy women (currently not having COVID-19). The question of CHC or MHT discontinuing or switching to other forms by women with COVID-19 should be decided depending on the severity of the disease, the total set of risk factors for thromboembolic complications and other individual characteristics of the clinical situation. Further research will provide elaboration of more detailed algorithms. Physicians need to be vigilant about the safety of compounded Bioidentical Hormonal Therapy (cBHT) in any dosage form (including pellets), especially during the COVID-19 pandemic, given the unexplored systemic effects and therefore the potential risks. Preference should be given to officially licensed medicinal products with a well-studied safety profile and clinical effects, the use of which is authorized by doctor's prescription and supported by clinical protocols and guidelines.

show abstract

Defining bioidentical hormones for menopause-related symptoms

Cited by 14 publications

References 12 publications

Women, the menopause, hormone replacement therapy and coronary heart disease

Women, the menopause, hormone replacement therapy and coronary heart disease

Use of Menopausal Hormone Therapy and Bioidentical Hormone Therapy in Australian Women 50 to 69 Years of Age: Results from a National, Cross-Sectional Study

On the use of sex steroids in women during the COVID-19 pandemic

Contact Info

Product

Resources

About